Clinical Trial: A Randomized Phase II Trial of SBRT Followed by Iparomlimab and Tuvonralimab Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Therapy for PD-L1-Negative or Low-Expressing Oligometastatic Non-Small Cell Lung Cancer (China)

China, Sept. 21 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Randomized Phase II Trial of SBRT Followed by Iparomlimab and Tuvonralimab Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Therapy for PD-L1-Negative or Low-Expressing Oligometastatic Non-Small Cell Lung Cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133003

Registration Time: 2026/09/21

Type: Interventional study

Primary Sponsor: Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=342223

Published by HT Digital Content...